Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Further Reading from MarketBeat Is Abbott's January Pullback a Good Time to Buy? Author: Thomas Hughes. Article Published: 1/24/2026. 
Quick Look - Abbott Laboratories’ January pullback looks driven more by sentiment than fundamentals, putting shares back near a prior accumulation zone.
- Quarterly results showed solid sales growth, improving margins, and faster adjusted earnings growth despite a revenue miss.
- A long dividend-growth track record and potential upside implied by analyst targets underpin the bullish rebound case.
Abbott Laboratories' (NYSE: ABT) January 2026 price pullback has made the stock look attractively valued. The decline appears driven more by market angst than by fundamental weaknesses — a knee-jerk overreaction that has pushed the shares back into a buy zone. 
This buy zone aligns with the 2022–2024 trading range, when Abbott was recovering from its post-COVID-19 revenue contraction and institutions were actively accumulating shares. Abbott Laboratories Growth Accelerates The most that can be said about Abbott Laboratories' Q4 results and guidance is that some metrics fell short of market expectations. Still, revenue of $11.46 billion (up 4.5% year over year), improved margins, and accelerated adjusted earnings make for a constructive report. Revenue growth missed by several hundred basis points, but margin strength helped offset that shortfall: adjusted earnings per share (EPS) rose about 12%, slightly above consensus. By segment, the results highlighted the strength of Abbott's diversified healthcare portfolio. Nutrition and Diagnostics contracted — Nutrition declined nearly 9% — but solid growth in Established Pharmaceuticals and Med Tech more than offset those weaknesses. Established Pharmaceuticals grew roughly 9%, driven by generics and emerging markets, while Med Tech expanded about 12.3%, showing strength across subsegments. Margin performance was generally positive. A favorable product mix, Med Tech strength, reduced COVID-19 sales and operational improvements left margins in a better position than many expected, even if some analyst forecasts were still missed. Management expects this momentum to continue, forecasting earnings growth of about 10% in 2026 — outpacing revenue growth — which should support the company's capital-return plans. Abbott's capital returns are central to the buying thesis. The company is a Dividend King, having raised its payout annually for more than 50 consecutive years, and it appears positioned to continue that trend. After the pullback, the stock yields roughly 2.5%, and the payout ratio sits below 50% of expected earnings, leaving room for share buybacks — a key offset to dilution from share-based compensation. Analysts Point to Robust Rebound in Abbott Laboratories Stock Some analysts flagged the revenue miss, but no major rating or price-target cuts were issued the morning of the release. The prevailing view is that this fundamentally healthy company can continue returning capital while reinvesting in growth, and the growth runway remains substantial. The consensus share price target reported by MarketBeat implies as much as ~30% upside, potentially pushing the stock to new all-time highs, while even the low-end targets suggest some upside from current levels. Key catalysts include an expanding Med Tech portfolio, AI integration across operations and products, widening margins and strategic acquisitions. The acquisition of Exact Sciences, for example, would expand Abbott's revenue and profit streams as well as its product pipeline. The recent decline has been sharp and could deepen, but institutions that added shares throughout 2025 are likely buyers at these discounted prices. Early indications show tentative support in the $105–$110 range, though that level is not yet confirmed. The risk is that ABT could slip to the low end of the target buy zone — possibly near $95 or below — before it rebounds.
| 
